Asllanaj, E.* ; Zhang, X.* ; Ochoa Rosales, C.* ; Nano, J. ; Bramer, W.M.* ; Portilla-Fernandez, E.* ; Braun, K.V.E.* ; Gonzalez-Jaramillo, V.* ; Ahrens, W.* ; Ikram, A.* ; Ghanbari, M.* ; Voortman, T.* ; Franco, O.H.* ; Muka, T.* ; Glisic, M.*
Sexually dimorphic DNA-methylation in cardiometabolic health: A systematic review.
Maturitas 135, 6-26 (2020)
Sex is a major determinant of cardiometabolic risk. DNA methylation (DNAm), an important epigenetic mechanism that differs between sexes, has been associated with cardiometabolic diseases. Therefore, we aimed to systematically review studies in adults investigating sex-specific associations of DNAm with intermediate cardiometabolic traits and incident cardiovascular disease including stroke, myocardial infarction (MI) and coronary heart disease (CHD). Five bibliographic databases were searched from inception to 15 July 2019. We selected 35 articles (based on 30 unique studies) from 17,023 references identified, with a total of 14,020 participants of European, North American or Asian ancestry. Four studies reported sex differences between global DNAm and blood lipid levels and stroke risk. In 25 studies that took a genome wide or candidate gene approach, DNAm at 31 gene sites was associated with sex differences in cardiometabolic diseases. The identified genes were PLA2G7, BCL11A, KDM6A, LIPC, ABCG1, PLTP, CETP, ADD1, CNN1B, HOOK2, GFBP-7,PTPN1, GCK, PTX3, ABCG1, GALNT2, CDKN2B, APOE, CTH, GNASAS, INS, PON1, TCN2, CBS, AMT, KDMA6A, FTO, MAP3K13, CCDC8, MMP-2 and ER-a. Prioritized pathway connectivity analysis associated these genes with biological pathways such as vitamin B12 metabolism, statin pathway, plasma lipoprotein, plasma lipoprotein assembly, remodeling and clearance and cholesterol metabolism. Our findings suggest that DNAm might be a promising molecular strategy for understanding sex differences in the pathophysiology of cardiometabolic diseases and that future studies should investigate the effects of sex on epigenetic mechanisms in cardiometabolic risk. In addition, we emphasize the gap between the translational potential and the clinical utilization of cardiometabolic epigenetics.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
Publication type
Article: Journal article
Document type
Review
Thesis type
Editors
Keywords
Dna Methylation ; Type 2 Diabetes ; Coronary Disease ; Myocardial Infarction ; Stroke; Coronary-heart-disease; Genome-wide Association; Essential-hypertension; Epigenetic Regulation; Apolipoprotein-e; Lipid-levels; Cardiovascular-disease; Metabolic Syndrome; Gene-expression; Risk-factors
Keywords plus
Language
english
Publication Year
2020
Prepublished in Year
HGF-reported in Year
2020
ISSN (print) / ISBN
0378-5122
e-ISSN
0378-5122
ISBN
Book Volume Title
Conference Title
Conference Date
Conference Location
Proceedings Title
Quellenangaben
Volume: 135,
Issue: ,
Pages: 6-26
Article Number: ,
Supplement: ,
Series
Publisher
Elsevier
Publishing Place
Elsevier House, Brookvale Plaza, East Park Shannon, Co, Clare, 00000, Ireland
Day of Oral Examination
0000-00-00
Advisor
Referee
Examiner
Topic
University
University place
Faculty
Publication date
0000-00-00
Application date
0000-00-00
Patent owner
Further owners
Application country
Patent priority
Reviewing status
Peer reviewed
Institute(s)
Institute of Epidemiology (EPI)
POF-Topic(s)
30202 - Environmental Health
90000 - German Center for Diabetes Research
Research field(s)
Genetics and Epidemiology
PSP Element(s)
G-504000-002
G-504000-010
G-501900-401
Grants
Copyright
Erfassungsdatum
2020-03-11